Have a feature idea you'd love to see implemented?
Let us know!
CORT Corcept Therapeutics Inc
Price (delayed)
$47.24
Market cap
$4.94B
P/E Ratio
38.72
Dividend/share
N/A
EPS
$1.22
Enterprise value
$4.81B
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym®
Highlights
The company's equity rose by 41% YoY and by 9% QoQ
The EPS has grown by 37% year-on-year and by 6% since the previous quarter
The P/E is 68% more than the 5-year quarterly average of 23.1 and 39% more than the last 4 quarters average of 27.8
Key stats
What are the main financial stats of CORT
Market
Valuations
Earnings
Shares outstanding
104.49M
Market cap
$4.94B
Enterprise value
$4.81B
Price to earnings (P/E)
38.72
Price to book (P/B)
8.25
Price to sales (P/S)
8.55
EV/EBIT
37.93
EV/EBITDA
37.58
EV/Sales
8.45
Revenue
$569.61M
EBIT
$126.9M
EBITDA
$128.08M
Free cash flow
$123.28M
Per share
Balance sheet
Liquidity
EPS
$1.22
Free cash flow per share
$1.2
Book value per share
$5.73
Revenue per share
$5.52
TBVPS
$6.93
Total assets
$714.56M
Total liabilities
$118.31M
Debt
$5.67M
Equity
$596.24M
Working capital
$460.1M
Debt to equity
0.01
Current ratio
5.57
Quick ratio
5.23
Net debt/EBITDA
-0.96
Margins
Efficiency
Dividend
EBITDA margin
22.5%
Gross margin
98.5%
Net margin
21.9%
Operating margin
22.5%
Return on assets
19.3%
Return on equity
23.7%
Return on invested capital
30.9%
Return on capital employed
20.7%
Return on sales
22.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CORT stock price
How has the Corcept Therapeutics stock price performed over time
Intraday
-1.71%
1 week
0.15%
1 month
7.36%
1 year
68.41%
YTD
45.44%
QTD
2.07%
Financial performance
How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$569.61M
Gross profit
$561.03M
Operating income
$127.94M
Net income
$124.95M
Gross margin
98.5%
Net margin
21.9%
CORT's net income is up by 33% YoY and by 7% QoQ
The revenue rose by 33% year-on-year and by 9% since the previous quarter
The gross profit is up by 33% year-on-year and by 9% since the previous quarter
Corcept Therapeutics's operating income has increased by 29% YoY and by 4.9% from the previous quarter
Growth
What is Corcept Therapeutics's growth rate over time
Valuation
What is Corcept Therapeutics stock price valuation
P/E
38.72
P/B
8.25
P/S
8.55
EV/EBIT
37.93
EV/EBITDA
37.58
EV/Sales
8.45
The P/E is 68% more than the 5-year quarterly average of 23.1 and 39% more than the last 4 quarters average of 27.8
The EPS has grown by 37% year-on-year and by 6% since the previous quarter
The stock's price to book (P/B) is 62% more than its 5-year quarterly average of 5.1 and 42% more than its last 4 quarters average of 5.8
The company's equity rose by 41% YoY and by 9% QoQ
CORT's P/S is 43% above its last 4 quarters average of 6.0 and 40% above its 5-year quarterly average of 6.1
The revenue rose by 33% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is Corcept Therapeutics business performance
The return on equity is up by 21% year-on-year but it has declined by 2.1% since the previous quarter
CORT's return on assets is up by 16% year-on-year
CORT's ROIC is down by 10% since the previous quarter but it is up by 8% year-on-year
The return on sales has declined by 3.5% since the previous quarter and by 3% year-on-year
Dividends
What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CORT.
Financial health
How did Corcept Therapeutics financials performed over time
The company's total assets rose by 36% YoY and by 9% QoQ
The quick ratio is up by 23% year-on-year and by 8% since the previous quarter
Corcept Therapeutics's debt is 99% lower than its equity
The company's equity rose by 41% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.